Dysphagia Days as an Assessment of Clinical Treatment Outcome in Eosinophilic Esophagitis.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 36647838.
- Also identified by DOI 10.14309/ajg.0000000000002094 and PMC identifier 10045973.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
The aim of this study was to evaluate Dysphagia Days as a measure of symptom improvement in patients with eosinophilic esophagitis from the HEROES study. Dysphagia Days, defined as a yes answer to the following question: During any meal today, did food go down slowly or get stuck in your throat or chest? was assessed for cendakimab vs placebo. A statistically significant reduction in the mean number of Dysphagia Days experienced was observed with cendakimab 360 mg vs placebo at week 16 (-4.67 vs -1.83; P = 0.0115); an even greater improvement was observed in steroid-refractory patients vs placebo (-4.48 vs -0.04; P = 0.0079). Dysphagia Days represents a relevant clinical end point to capture dysphagia-related symptoms.
Medical subject headings
- Enteritis
- Deglutition Disorders
- Esophagitis
- Eosinophilic Esophagitis